Neurological conditions are now the leading cause of ill health and disability globally, affecting 3.4 billion people worldwide. Collectively, neurodevelopmental and neurodegenerative disorders account for more than 60% of this disease burden.1
Our development programs are focused on developing better treatments for Neurodevelopmental and Neurodegenerative disorders.
AFX-220 is our clinical stage proven drug that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD and others. AFX-220 acts on multiple disease associated dysregulated pathways including monoamine neurotransmitters and cytokine associated inflammatory modulators.
AFX-770 is our late pre-clinical stage de-risked drug that is intended to treat neurogenerative disorders such as Parkinson's disease, Frontotemporal lobar dementia and others. AFX-770 acts on multiple disease associated dysregulated pathways including neurotransmitters and inhibition of glial cell activation.
References:
- The Lancet Neurology - March 14, 2024